Sarcopenia and Systemic Therapy in HCC

Recruiting now

Conditions studied: HCC - Hepatocellular Carcinoma

In brief

This is a multi-center, retrospective observational study in patients with liver cancer (HCC) to assess the impact of sarcopenia (muscle loss) on the prognosis, duration, and tolerance of systemic treatment.

Key facts

Study ID

NCT06805552

Run by

IRCCS Azienda Ospedaliero-Universitaria di Bologna

People needed

270

Starts

2022-10-19

Expected to finish

2025-11-01

Last updated by the study team

2025-02-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged ≥18 years.
• Diagnosis of hepatocellular carcinoma based on histological and/or radiological results as defined by the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD). The staging of hepatocellular carcinoma was obtained through contrast-enhanced liver CT and/or MRI.
• Patients with advanced (BCLC-C) or intermediate (BCLC-B) stage hepatocellular carcinoma, or patients with early-stage (BCLC-A) hepatocellular carcinoma who have not responded to previous locoregional ablative treatments and/or liver resection.
• Treatment with TKIs according to the indications and prescription criteria defined by AIFA, with no requirement to reach a minimum treatment period.
• Availability of a CT scan performed within no more than 8 weeks prior to the start of TKI therapy.
• Obtaining written informed consent.

You may not qualify if…

• None

Where it is running

• IRCCS AOUBO Policlinico di S.Orsola — Bologna, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.